Dinlas Pharma EPZ Ltd Faces Scrutiny Over Alleged Employee Mistreatment and Controversial Manufacturing/Expiry Date Irregularities
An exposé has revealed mistreatment of employees at Dinlas Pharma EPZ Ltd, shedding light on controversial discrepancies in manufacturing and expiry dates.
After enduring years of
hardship, employees of Dinlas Pharma EPZ Ltd have bravely come forward to shed
light on the challenging work environment they have been subjected to.
The company has faced
serious allegations from both current and former employees, including reports
of unsafe working conditions, inadequate compensation, and intimidation
tactics.
According to accounts
from current and former employees, workers at the facility have been regularly
handling hazardous materials without the necessary protective gear, exposing
them to the risk of workplace accidents, chemical burns, and long-term health
issues.
These safety concerns
are further compounded by claims of stagnant wages that have failed to keep up
with the rising cost of living in Kenya. Employees have also voiced grievances about being required to
work additional shifts, cover for absent colleagues, and report to work on
public holidays without receiving overtime pay or extra allowances.
In addition to the lack
of compensation for extra duties, workers have reported facing retaliation when
attempting to raise concerns about their pay, safety standards, or working
conditions. Allegations suggest that
employees who question these issues often face intimidation or unjust
dismissal, particularly at the time of contract renewal.
These claims paint a
troubling picture of a profitable enterprise that allegedly prioritizes financial
gain over the well-being of its employees, a concern echoed by labor advocates
familiar with challenges in Kenya’s industrial sector.
Calls have now been
made for labor rights groups and relevant authorities to investigate whether
Dinlas Pharma EPZ Ltd is adhering to the Employment Act, the Occupational
Safety and Health Act (OSHA), and minimum wage regulations.
As the allegations
continue to gain attention, employees emphasize their fundamental demands: fair
compensation, safe working conditions, and the freedom to speak out without
fear of reprisal.
Another Kenyan has also demanded answers.
I was issued children's syrup from a government facility with
the following details:
Date of manufacture: October 2023
Expiry date: September 2026
Date issued to patient: May 2026
The medicine in question is PARADOL (Paracetamol Oral Solution
BP), manufactured by Dinlas Pharma EPZ Ltd in Mombasa, Kenya. The packaging
appears professionally printed and bears the manufacturer's details and a
registration number.
My concern is whether it is normal for children's syrups to
remain in government stores and health facilities for such a long period before
being dispensed to patients. By the time the medicine was issued, it only had a
few months remaining before expiry.
As a parent with a young family, I have noticed that some syrups
issued from government facilities appear to be approaching their expiry dates.
This has raised questions in my mind about stock management, inventory
turnover, and how medicines are distributed within public health facilities.
I am not making any allegations and I do not have sufficient
information to draw any conclusions. However, I would appreciate hearing from
pharmacists, medical practitioners, supply chain experts, and other parents who
may have had similar experiences, particularly in Nairobi and other government
health facilities across the country.
Is it standard practice for medicines manufactured in 2023 to
still be in circulation and being dispensed in 2026 if they remain within their
approved shelf life? How does the government pharmaceutical supply chain manage
stock rotation for commonly used pediatric medicines?
I am also interested in knowing whether other parents have
received medicines with similar manufacturing and expiry timelines from
government facilities and whether this is considered normal within the
healthcare system.
I am simply seeking information and public views to better
understand how these medicines move through the public healthcare supply chain
and whether there is anything that members of the public should know when
receiving medicines that are nearing their expiry dates.
Thank you.


Comments
Post a Comment